Overview
Kisspeptin (encoded by the KISS1 gene) is a family of neuropeptides produced primarily in the hypothalamus that act as the primary upstream regulator of gonadotropin-releasing hormone (GnRH) pulsatility. The kisspeptin system was discovered in 2003 when KISS1 receptor mutations were found to cause hypogonadotropic hypogonadism. Since then, it has been established as the central regulator of puberty onset, the hypothalamic-pituitary-gonadal (HPG) axis, and reproductive cyclicity. Kisspeptin neurons (KNDy neurons, co-expressing kisspeptin, neurokinin B, and dynorphin) in the arcuate nucleus of the hypothalamus are directly responsible for generating the GnRH pulse rhythm. At menopause, the loss of estrogen negative feedback causes these neurons to become hyperactive, producing the erratic GnRH/LH surges that underlie hot flashes and night sweats. This makes the kisspeptin system one of the most mechanistically direct research targets in menopausal symptom biology.
Mechanism
Kisspeptin binds to the kisspeptin receptor (KISS1R, formerly GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. The KNDy neuron circuit uses neurokinin B (NKB) as an accelerator and dynorphin as a brake to generate the rhythmic GnRH pulses that drive LH/FSH and downstream sex hormone production. In post-menopausal women, estrogen withdrawal disinhibits NKB signaling in the arcuate nucleus, causing neurokinin B receptor hyperactivation — the mechanistic basis for hot flashes. NK3 receptor antagonists (fezolinetant) are now FDA-approved for this mechanism. Kisspeptin research focuses on modulating this system more proximally.
Research Areas
Side Effects (Preclinical)
- – Nausea (dose-dependent)
- – Transient flushing
- – LH surge and associated hormonal fluctuations
Cautions
- – Primarily studied in human research via IV administration
- – Effects are highly dose- and context-dependent (stimulatory vs. desensitizing at high doses)
- – Active area of pharmaceutical development — clinical trial landscape evolving rapidly
Menopause & Women's Health Relevance
Kisspeptin neurons are the direct source of the hormonal chaos at menopause. When estrogen drops, these neurons lose their inhibitory feedback signal and become hyperactive — producing the erratic GnRH/LH surges responsible for hot flashes and night sweats. Understanding (and potentially modulating) the kisspeptin pathway is one of the most mechanistically targeted approaches to menopausal symptom research. The 2023 FDA approval of fezolinetant (an NKB receptor antagonist in the same circuit) validates this pathway clinically.
What the research shows
Kisspeptin is the closest thing to a “master switch” for the reproductive hormone axis that peptide research has identified. The discovery that KISS1R mutations cause complete reproductive failure in humans (Seminara et al., 2003) established kisspeptin as non-redundant in reproduction — it cannot be bypassed.
The menopause connection is mechanistically direct. Estrogen normally suppresses kisspeptin/NKB activity in arcuate KNDy neurons. When estrogen falls at menopause, that brake is removed. NKB signaling surges, driving erratic GnRH and LH pulses — the physiological event experienced as a hot flash.
The 2023 FDA approval of fezolinetant (Veoza), an NK3R antagonist targeting the same KNDy circuit, validated this pathway as a drug target and represents the first non-hormonal menopause treatment approved based on this mechanism.
References
- Kisspeptin and the Hypothalamic Control of Reproduction — Roa J et al. (2008)
- Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes — Prague JK et al. (2017)